TrialScope Disclose offers a simple, refined solution that streamlines and accelerates disclosure while minimizing risk and maximizing transparency.

Accelerated Clinical Trial Disclosure Starts Here

TrialScope Disclose is the leading global clinical disclosure software, trusted by 16 of the top 20 Pharmaceutical companies. The latest enhancement TrialScope Disclose: Core Data simplifies the registry submission and approval process by consolidating data for multiple registries into one single form.

How can Core Data help you?

Keep Data Consistent

Eliminate Duplication

Save Time

Minimize Compliance Risks

Reduce Stakeholder Questions

Enable Global Harmonization

Learn More about TrialScope Disclose: Core Data

Harmonization of Global Data: Bridging the Gaps Among Local Registries

When a leading pharmaceutical company sought a solution to remove bottlenecks in its clinical trial disclosure process, it turned to TrialScope Disclose: Core Data. This tool streamlined the process while ensuring data accuracy and compliance.

PDF preview of the TrialScope Disclose white paper.
Precision in Practice: Unlocking Efficiency with TrialScope Disclose: Core Data

When a leading pharmaceutical company sought a solution to remove bottlenecks in its clinical trial disclosure process, it turned to TrialScope Disclose: Core Data. This tool streamlined the process while ensuring data accuracy and compliance.

PDF preview of the TrialScope Disclose Use Case.
Accelerated Clinical Trial Disclosure Starts Here

Discover how to gain control of your disclosure processes, increase transparency and build your organization’s reputation, starting with TrialScope Disclose.

PDF preview of the TrialScope Disclose flyer.
Request a Demo
Professionals submitting a form to find out more about Citeline.

Citeline may contact you about relevant products, services and content. To opt-out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.